Compare · CDNA vs CI
CDNA vs CI
Side-by-side comparison of CareDx Inc. (CDNA) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $74.62B, about 57.7x CDNA ($1.29B).
- CDNA has been more active in the news (14 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 18 for CDNA).
- Company
- CareDx Inc.
- The Cigna Group
- Price
- -
- -
- Market cap
- $1.29B
- $74.62B
- 1M return
- +16.19%
- -
- 1Y return
- +32.07%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 14
- 4
- Recent ratings
- 18
- 25
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CDNA
- President and CEO Hanna John Walter Jr sold $424,877 worth of shares (17,683 units at $24.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 631,959 units (SEC Form 4)
- Director Valantine Hannah was granted 9,795 shares and sold $279,728 worth of shares (12,103 units at $23.11) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,686 units (SEC Form 4)
- Director Cournoyer Christine was granted 9,795 shares, increasing direct ownership by 20% to 58,943 units (SEC Form 4)
- Director Riggsbee Richard Bryan was granted 9,795 shares, increasing direct ownership by 33% to 39,312 units (SEC Form 4)
- Director Cohen Fred E was granted 9,795 shares, increasing direct ownership by 6% to 165,060 units (SEC Form 4)
- Director Gunasekaran Suresh was granted 9,795 shares, increasing direct ownership by 36% to 37,248 units (SEC Form 4)
- Director Bickerstaff George was granted 9,795 shares, increasing direct ownership by 7% to 154,061 units (SEC Form 4)
- Director Goldberg Michael was granted 9,795 shares, increasing direct ownership by 5% to 195,737 units (SEC Form 4)
- CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
- President and CEO Hanna John Walter Jr sold $528,443 worth of shares (21,998 units at $24.02) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 649,642 units (SEC Form 4)
Latest CI
- The Cigna Group Foundation Invests $3 Million to Strengthen Youth Mental Health Through Nonprofits Across 10 States
- Chief Accounting Officer Kates Jamie G exercised 899 shares at a strike of $152.89 and sold $268,452 worth of shares (899 units at $298.61) (SEC Form 4)
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director